Top

Published in:

Open Access 01-12-2019 | Breast Cancer | Research article

Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer

Authors: Yaping Yang, Ying Wang, Heran Deng, Cui Tan, Qian Li, Zhanghai He, Wei Wei, Enxiang Zhou, Qiang Liu, Jieqiong Liu

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Triple negative breast cancer (TNBC) is an aggressive and heterogeneous disease. Nomograms predicting outcomes of TNBC are needed for risk management.

Methods

Nomograms were based on an analysis of 296 non-metastatic TNBC patients treated at Sun Yat-sen Memorial Hospital from 2002 to 2014. The end points were disease-free survival (DFS) and overall survival (OS). Predictive accuracy and discriminative ability were evaluated by concordance index (C-index), area under the curve (AUC) and calibration curve, and compared with the American Joint Committee on Cancer (AJCC) staging system, PREDICT and CancerMath. Models were subjected to bootstrap internal validation and external validation using independent cohorts of 191 patients from the second Xiangya Hospital and Peking University Shenzhen Hospital between 2007 and 2012.

Results

On multivariable analysis of training cohort, independent prognostic factors were stromal tumor-infiltrating lymphocytes (TILs), tumor size, node status, and Ki67 index, which were then selected into the nomograms. The calibration curves for probability of DFS and OS showed optimal agreement between nomogram prediction and actual observation. The C-index of nomograms was significantly higher than that of the seventh and eighth AJCC staging system for predicting DFS (training: 0.743 vs 0.666 (P = 0.003) and 0.664 (P = 0.024); validation: 0.784 vs 0.632 (P = 0.02) and 0.607 (P = 0.002)) and OS (training: 0.791 vs 0.683 (P = 0.004) and 0.677 (P < 0.001); validation: 0.783 vs 0.656 (P = 0.006) and 0.606 (P = 0.001)). Our nomograms had larger AUCs compared with PREDICT and CancerMath. In addition, the nomograms showed good performance in stratifying different risk groups of patients both in the training and validation cohorts.

Conclusion

We have developed novel and practical nomograms that can provide individual prediction of DFS and OS for TNBC based on stromal TILs, tumor size, node status, and Ki67 index. Our nomograms may help clinicians in risk consulting and selection of long term survivors.

Available only for authorised users

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–42.PubMedCrossRef

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90.PubMedPubMedCentralCrossRef

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef

Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982;45(3):361–6.PubMedPubMedCentralCrossRef

Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.PubMedCrossRef

Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.PubMedPubMedCentralCrossRef

Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, et al. PREDICT plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7.PubMedPubMedCentralCrossRef

Kim W, Kim KS, Lee JE, Noh DY, Kim SW, Jung YS, Park MY, Park RW. Development of novel breast cancer recurrence prediction model using support vector machine. J Breast Cancer. 2012;15(2):230–8.PubMedPubMedCentralCrossRef

Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat. 2011;128(3):827–35.PubMedCrossRef

10.

Mazouni C, Spyratos F, Romain S, Fina F, Bonnier P, Ouafik LH, Martin PM. A nomogram to predict individual prognosis in node-negative breast carcinoma. Eur J Cancer. 2012;48(16):2954–61.PubMedCrossRef

11.

Campbell HE, Gray AM, Harris AL, Briggs AH, Taylor MA. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer. 2010;103(6):776–86.PubMedPubMedCentralCrossRef

12.

Fan YP, Liu CL, Chiang IJ, Lin CY. Development of a prognostic nomogram for identifying those factors which influence the 2- and 5-year survival chances of Taiwanese women diagnosed with breast cancer. Eur J Cancer Care. 2011;20(5):620–6.CrossRef

13.

Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, et al. Personalized prognostic prediction models for breast Cancer recurrence and survival incorporating multidimensional data. J Natl Cancer Inst. 2017;109(7).

14.

Candido Dos Reis FJ, Wishart GC, Dicks EM, Greenberg D, Rashbass J, Schmidt MK, van den Broek AJ, Ellis IO, Green A, Rakha E, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. 2017;19(1):58.PubMedPubMedCentralCrossRef

15.

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011;11:299.PubMedPubMedCentralCrossRef

16.

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.PubMedCrossRef

17.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.PubMedCrossRef

18.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50.PubMedCrossRef

19.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.PubMedPubMedCentralCrossRef

20.

Klebanoff MA, Cole SR. Use of multiple imputation in the epidemiologic literature. Am J Epidemiol. 2008;168(4):355–7.PubMedPubMedCentralCrossRef

21.

Janssen KJ, Donders AR, Harrell FE Jr, Vergouwe Y, Chen Q, Grobbee DE, Moons KG. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol. 2010;63(7):721–7.PubMedCrossRef

22.

Liao SG, Lin Y, Kang DD, Chandra D, Bon J, Kaminski N, Sciurba FC, Tseng GC. Missing value imputation in high-dimensional phenomic data: imputable or not, and how? BMC bioinformatics. 2014;15:346.PubMedPubMedCentralCrossRef

23.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259–71.PubMedCrossRef

24.

Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z, Deng Q, Xiong X, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.PubMedCrossRef

25.

Harrell FE Jr. Regression Modeling Strategies. New York: Springer -Verlag; 2001.CrossRef

26.

Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–43.PubMedCrossRef

27.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.PubMedCrossRef

28.

Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89.PubMedCrossRef

29.

Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, Youn HJ. Basic findings regarding breast Cancer in Korea in 2015: data from a breast Cancer registry. J Breast Cancer. 2018;21(1):1–10.PubMedPubMedCentralCrossRef

30.

Ko BS, Noh WC, Kang SS, Park BW, Kang EY, Paik NS, Yang JH, Ahn SH. Changing patterns in the clinical characteristics of korean breast cancer from 1996-2010 using an online nationwide breast cancer database. J Breast Cancer. 2012;15(4):393–400.PubMedPubMedCentralCrossRef

31.

Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer. 2009;100(4):563–70.PubMedPubMedCentralCrossRef

32.

Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011;11:364.PubMedPubMedCentralCrossRef

33.

Lu WL, Li HX, Qian BY, Wang Y, Jansen L, Huang GW, Tang NJ, Sun Z, Chen KX, De Bock GH. The clinical characteristics and prognosis of Chinese early stage breast cancer patients: a retrospective study. Breast J. 2010;16(3):331–3.PubMedCrossRef

34.

Huang L, Liu Z, Chen S, Liu Y, Shao Z. A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. PLoS One. 2013;8(12):e83081.PubMedPubMedCentralCrossRef

35.

Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307.PubMedPubMedCentralCrossRef

36.

Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22.PubMedPubMedCentralCrossRef

Title: Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
Authors: Yaping Yang
Ying Wang
Heran Deng
Cui Tan
Qian Li
Zhanghai He
Wei Wei
Enxiang Zhou
Qiang Liu
Jieqiong Liu
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5703-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation

miR-196a-5p promotes metastasis of colorectal cancer via targeting IκBα

Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia

PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway

Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer